Publications by authors named "Marguerite M Patel"
PT150, a novel competitive glucocorticoid receptor (GR) antagonist, has proven safe in animal models, healthy volunteers, and people with depression. Our study is the first to investigate PT150's safety with alcohol use. The primary objective of this study was to evaluate pharmacodynamic interactions between ethanol and PT150 in healthy subjects.
View Article and Find Full Text PDFArticle Synopsis
- No FDA-approved medications currently exist for cannabis use disorder (CUD), and this study explored the short-term effects of guanfacine, an α-2A-adrenergic receptor agonist, on withdrawal symptoms in volunteers with CUD.
- Volunteers (n=7) who met CUD criteria underwent a two-phase study, alternating between guanfacine and a placebo while assessing withdrawal symptoms, sleep, craving, and physiology.
- While guanfacine did not significantly improve withdrawal symptoms or craving, there were trends indicating it might enhance positive mood and reduce craving-related compulsivity, suggesting that further research on guanfacine for CUD treatment is needed.
Background And Objectives: The endogenous cannabinoid anandamide (AEA), an agonist at type-1 cannabinoid (CB1) receptors, is metabolized by fatty acid amide hydrolase (FAAH). The common variant rs324420 C->A within the FAAH gene on chromosome 1 codes for a missense substitution (Pro129Thr), resulting in decreased FAAH activity and increased endocannabinoid potentiation. This FAAH variant has been linked to alterations in mood and stress reactivity, as well as being independently linked to increased risk for addiction.
View Article and Find Full Text PDFPurpose: To create a standardized method for evaluating the video recordings of patients self-instilling eye drops and to determine the level of agreement of eye drop instillation efficacy, safety and efficiency ratings by three masked graders.
Design: Prospective cross-sectional study.
Participants: 78 patients with open-angle glaucoma or ocular hypertension who had at least 6 months of experience with the use of eye drop medications.